Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa.
about
Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia.Trends in the development of oral anticoagulants.Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.Thromboprophylaxis with apixaban and the risk of pulmonary embolism in patients undergoing knee replacement surgeryPatient Taking A Novel Oral Anticoagulant Presents With Major GI Bleeding.Antithrombotic Usage Patterns in the Era of New Oral Anticoagulant Options for Atrial Fibrillation.Parenteral administration of factor Xa/IIa inhibitors limits experimental aortic aneurysm and atherosclerosis.Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants.Reversal of drug-induced anticoagulation: old solutions and new problems.Advances in the diagnosis and treatment of acute pulmonary embolism.Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery.New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures.Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials.Working toward precision medicine: Predicting phenotypes from exomes in the Critical Assessment of Genome Interpretation (CAGI) challenges.Rate-limiting roles of the tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow.Evaluation of Potential Thrombin Inhibitors from the White Mangrove (Laguncularia racemosa (L.) C.F. Gaertn.).Dabigatran for thromboprophylaxis after robotic assisted laparoscopic prostatectomy: retrospective analysis of safety profile and effect on blood coagulation.In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban.Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation.A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation.Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation.Inverse relationship of bleeding risk with clot burden during pulmonary embolism treatment with LMW heparin.Anticoagulation therapy and proximal femoral fracture treatment: An update.Investigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects.A comparison of apixaban and dabigatran etexilate for thromboprophylaxis following hip and knee replacement surgery.Bioassay-guided fractionation of Melastoma malabathricum Linn. leaf solid phase extraction fraction and its anticoagulant activity.Direct Oral Anticoagulants in Dental Patients Including the Frail Elderly Population.
P2860
Q33407198-694AD2EA-BC6A-41ED-9053-3ACE3F7ABE14Q33424198-7FBCBF16-60F3-45DD-ADED-2558BDC3A775Q34284362-F8A5D9E2-EA7D-43F7-8537-4DFFA09F6AA3Q34570893-59FAC011-246A-4C88-8195-9F727C0D30ACQ36021499-E9A34237-70FC-4603-B443-5F8D355F3CD3Q37114565-F57F7BD3-B181-4EB6-881C-51E39DDFD615Q37167694-795436AF-3447-4EB1-9D01-FBFB67AB9807Q37654883-2E1DAEC9-4F9E-4B91-9D42-17AAF9C615CEQ37955199-C95D1FB3-A9A3-4A34-A532-95B43692BA6BQ38009420-F79E103F-4E1B-4BD4-9327-01B146BFB58BQ38012449-5904191C-00D8-4052-B1E4-51018D925F78Q38017736-A6384F58-1135-47CB-AA45-A2E1957ABC73Q38068113-EBC161E7-F896-4079-BDBE-918EE2E2B1EAQ38584212-C7676A63-3864-4D2F-9C43-274D52B827E4Q38716169-3DB77B36-7AF5-4F33-BFB1-3BF7037210BEQ41226859-F08F81F3-F838-4B7D-BF37-6A2A1C5F9349Q42391725-4D5471BE-E90B-4E63-B0D7-82ADEBF4384CQ43718286-AF1F3D6E-8132-4A67-B8CE-68C98758D756Q44330030-841F60D0-6267-4512-869A-6CA9677F9A5CQ44690504-8100CEDE-FAE0-4015-94CA-FC3FEE97B384Q50485303-224547E8-50A7-4844-ABDB-B67EA5A3C1FAQ51367467-6B47DAB6-3263-41A3-BC89-672A2ABAEC45Q51664452-96293E60-E463-445C-A941-F24E41EB2946Q52809996-F9CA3885-5036-4EE9-936D-BC8F4060E36AQ53089410-BD9FB292-1D80-4B23-A0B1-C881F01BCD62Q53335452-B8C1C0AB-D9D7-4C54-8F3E-5B466EA85DCAQ53596125-08290A2D-2DDA-48B0-BA57-361BD91510F1Q55050376-271FA38F-E4C4-476E-A328-430BCB0B451B
P2860
Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Recent progress in anticoagula ...... ors of thrombin and factor Xa.
@en
Recent progress in anticoagula ...... ors of thrombin and factor Xa.
@nl
type
label
Recent progress in anticoagula ...... ors of thrombin and factor Xa.
@en
Recent progress in anticoagula ...... ors of thrombin and factor Xa.
@nl
prefLabel
Recent progress in anticoagula ...... ors of thrombin and factor Xa.
@en
Recent progress in anticoagula ...... ors of thrombin and factor Xa.
@nl
P2860
P1476
Recent progress in anticoagula ...... ors of thrombin and factor Xa.
@en
P2093
P2860
P356
10.1111/J.1538-7836.2011.04321.X
P478
P577
2011-07-01T00:00:00Z